Pharmacogenetic Testing in Primary Care Practice: Opinions of Physicians, Pharmacists and Patients

References

• Green JS , O’BrienTJ , ChiappinelliVA , HarralsonAF. Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine. Pharmacogenomics11(9), 1331–1340 (2010).
   PubMed Web of Science ®Google Scholar
• Dion-Labrie M , FortinMC , HébertMJ , DoucetH. Réflexion éthique sur la médecine personnalisée: l’alliance de la science et de la médecine enfin réalisée?Rev. Colomb. Bioét.3(2), 33–56 (2008).
   Google Scholar
• Commission De L’éthique En Science Et En Technologie (CEST) . Soins de santé personnalisés: document de consultation. QC, Canada (2012). www.ethique.gouv.qc.ca/fr/assets/documents/SSP/SSP_document_de_consultation_Web.pdf
   Google Scholar
• Spear BB , Heath-ChiozziM , HuffJ. Clinical application of pharmacogenetics. Trends Mol. Med.7(5), 201–204 (2001).
   PubMed Web of Science ®Google Scholar
• Lee JW , AminkengF , BhavsarAPet al. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin. Genet.86(1), 21–28 (2014).
   PubMed Web of Science ®Google Scholar
• Zed PJ , Abu-LabanRB , BalenRMet al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ178(12), 1563–1569 (2008).
   PubMed Web of Science ®Google Scholar
• PharmGKB . Drug label annotations (2018). www.pharmgkb.org/labelAnnotations
   Google Scholar
• Singh A . Pharmacogenomics: the potential of genetically guided prescribing. Austr. Fam. Phys.36(10), 820–824 (2008).
   Google Scholar
• Letarte N , LavoieA , SheehanNet al. La pharmacothérapie personnalisée et la pharmacogénétique. Pharmactuel46(4), 258–268 (2013).
   Google Scholar
• Ndegwa S . La pharmacogénomique et la warfarine [Notes sur les technologies de la santé en émergence]. Agence Canadienne des Médicaments et des technologies de la santé104, 1–8 (2007).
   Google Scholar
• Poncin J . Les Américains sont-ils favorables à la pharmacogénomique?L’Observatoire de la génétique (2003). www.omics-ethics.org/observatoire/zoom/zoom_03/z_no10_03/z_no10_03_2.html
   Google Scholar
• Gossard F , HametP. Pour distinguer génétique, génomique, pharmacogénétique et pharmacogénomique dans les problèmes éthiques. Les pratiques de recherche biomdicales visitées par la bioéthique (2003).
   Google Scholar
• Hall SS . Personalized medicine’s bitter pill. MIT Technology Review ( 2003). www.technologyreview.com/s/401777/personalized-medicines-bitter-pill/
   Google Scholar
• Rothstein MA . Pharmcogenomics Social, Ethical and Clinical Dimension. Éditions John Wiley & Sons (2003).
   Google Scholar
• Mallal S , PhillipsE , CarosiGet al. HLA-B*5701 screening for hypersensitivity to abacavir . N. Engl. J. Med.358(6), 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Pirmohamed M , BurnsideG , ErikssonNet al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med.369(24), 2294–2303 (2013).
   PubMed Web of Science ®Google Scholar
• Olson MC , MacielA , GariepyJFet al. Clinical impact of pharmacogenetic-guided treatment for patients exhibiting neuropsychiatric disorders: a randomized controlled trial. Prim Care Companion CNS Disord19(2), doi: 10.4088/PCC.16m02036. (2017).
   PubMedGoogle Scholar
• Bradley P , ShiekhM , MehraVet al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res96, 100–107 (2018).
   PubMed Web of Science ®Google Scholar
• Perez V , SalavertA , EspadalerJet al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry17(1), 250 (2017).
   PubMedGoogle Scholar
• Ielmini M , PoloniN , CaselliIet al. The utility of pharmacogenetic testing to support the treatment of bipolar disorder. Pharmgenomics Pers Med11, 35–42 (2018).
   PubMed Web of Science ®Google Scholar
• Wiltshire T , DongOM. Clinical pharmacogenetics: how do we ensure a favorable future for patients?Pharmacogenomics19(6), 553–562 (2018).
   PubMed Web of Science ®Google Scholar
• Drozda K , PacanowskiMA. Clinical trial designs to support clinical utility of pharmacogenomic testing. Pharmacotherapy37(9), 1000–1004 (2017).
   PubMed Web of Science ®Google Scholar
• Owusu Obeng A , FeiK , LevyKD et al. Physician-reported benefits and barriers to clinical implementation of genomic medicine: a multi-site IGNITE-network survey. J. Pers. Med.8(3), pii:E24 (2018).
   Web of Science ®Google Scholar
• Selkirk CG , WeissmanSM , AndersonA , HulickPJ. Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet. Test. Mol. Biomarkers17(3), 219–225 (2013).
   PubMed Web of Science ®Google Scholar
• Hull LE , LehmannLS , LynchJA. Gene-based prescribing is here – are providers ready?Am. J. Med.pii: S0002-9343(19)30231-1 (2019). ( Epub ahead of print).
   Google Scholar
• Birch L , PétryF. L’utilisation des groupes de discussion dans l’élaboration des politiques en santé. Recherches qualitatives29(3), 103–132 (2011).
   Google Scholar
• Rabiee F . Focus-group interview and data analysis. Proc. Nutr. Soc.63(4), 655–660 (2004).
   PubMed Web of Science ®Google Scholar
• Baribeau C , GermainM. L’entretien de groupe: considérations théoriques et méthodologiques. Recherches Qualitatives29(1), 28–49 (2010).
   Google Scholar
• Tong A , SainsburyP , CraigJ. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care19(6), 349–357 (2007).
   PubMed Web of Science ®Google Scholar
• Blackburn MÈ , GaudreaultM , TremblayJ-F , VeilletteS. Portrait des 16–24 ans sans diplôme résidant sur le territoire de la Commission scolaire de Charlevoix. 93 (2005).
   Google Scholar
• Blackburn M-È , JoyalI , BrooksS , TardifS , ArbourN. Étude sur l’abandon et la persévérance à la Mesure de formation de la main-d’œuvre d’Emploi-Québec. 98 (2013).
   Google Scholar
• Blackburn M-È , TardifS. Étude sur l’abandon et la persévérance de trois mesures d’aide à l’emploi d’Emploi-Québec. 61 (2016).
   Google Scholar
• Guest G , NameyE , McKennaK. How many focus groups are enough? Building an evidence base for nonprobability sample sizes. Field Methods29(1), 3–22 (2017).
   Web of Science ®Google Scholar
• Blackburn M-È . Les représentations sociales de la pharmacogénomique au Québec: éléments de prospective. Thèse de doctorat en sciences humaines appliquées415 (2012).
   Google Scholar
• Paillé P , MucchielliA. L’analyse qualitative en sciences humaines et sociales. (4th). ColinA (Ed.). Paris, France (2016).
   Google Scholar
• Miles MB , HubermanAM. Qualitative data analysis: An expanded sourcebook, 2nd ed.Sage Publications, Inc, CA, USA (1994).
   Google Scholar
• Denzin NK . Interpretive Interactionism. 2,Sage Publications, Inc, CA, USA (2001).
   Google Scholar
• Chan CY , ChuaBY , SubramaniamM , SuenEL , LeeJ. Clinicians’ perceptions of pharmacogenomics use in psychiatry. Pharmacogenomics18(6), 531–538 (2017).
   PubMed Web of Science ®Google Scholar
• De Denus S , LetarteN , HurlimannTet al. An evaluation of pharmacists’ expectations towards pharmacogenomics. Pharmacogenomics14(2), 165–175 (2013).
   PubMed Web of Science ®Google Scholar
• Mccullough KB , FormeaCM , BergKDet al. Assessment of the pharmacogenomics educational needs of pharmacists. Am. J. Pharm. Educ.75(3), 51 (2011).
   PubMed Web of Science ®Google Scholar
• Fargher EA , EddyC , NewmanWet al. Patients’ and healthcare professionals’ views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics8(11), 1511–1519 (2007).
   PubMed Web of Science ®Google Scholar
• Haga SB , BurkeW , GinsburgGS , MillsR , AgansR. Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clin. Genet.82(4), 388–394 (2012).
   PubMed Web of Science ®Google Scholar
• Stanek EJ , SandersCL , TaberKAet al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther.91(3), 450–458 (2012).
   PubMed Web of Science ®Google Scholar
• Cohn I , CohnRD , ItoS. Professional opportunity for pharmacists to integrate pharmacogenomics in medication therapy. Can. Pharm. J. (Ott)151(3), 167–169 (2018).
   PubMedGoogle Scholar
• Scheuner MT , SieverdingP , ShekellePG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA299(11), 1320–1334 (2008).
   PubMed Web of Science ®Google Scholar
• Peterson JF , FieldJR , ShiYet al. Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J.16(4), 393–398 (2016).
   PubMed Web of Science ®Google Scholar
• Haga SB , MillsR , MoaddebJ , LapointeNA , ChoA , GinsburgGS. Primary care providers’ use of pharmacist support for delivery of pharmacogenetic testing. Pharmacogenomics18(4), 359–367 (2017).
   PubMed Web of Science ®Google Scholar
• Payne K , FargherEA , RobertsSAet al. Valuing pharmacogenetic testing services: a comparison of patients’ and health care professionals’ preferences. Value Health14(1), 121–134 (2011).
   PubMed Web of Science ®Google Scholar
• Rogausch A , PrauseD , SchallenbergA , BrockmollerJ , HimmelW. Patients’ and physicians’ perspectives on pharmacogenetic testing. Pharmacogenomics7(1), 49–59 (2006).
   PubMed Web of Science ®Google Scholar
• Lemke AA , HuttenSelkirk CG , GlaserNSet al. Primary care physician experiences with integrated pharmacogenomic testing in a community health system. Per. Med.14(5), 389–400 (2017).
   PubMed Web of Science ®Google Scholar
• Albassam A , AlshammariS , OudaG , KoshyS , AwadA. Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait. PLoS One13(9), (2018).
   PubMed Web of Science ®Google Scholar
• Relling MV , KleinTE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther.89(3), 464–467 (2011).
   PubMed Web of Science ®Google Scholar
• Mcmahon T , TucciJ. The perceptions of pharmacists in Victoria, Australia on pharmacogenetics and its implications. Pharm. Pract. (Granada)9(3), 141–147 (2011).
   PubMedGoogle Scholar
• Tuteja S , HaynesK , ZayacC , SpragueJE , BernhardtB , PyeritzR. Community pharmacists’ attitudes towards clinical utility and ethical implications of pharmacogenetic testing. Per Med10(8), 793–800 (2013).
   PubMed Web of Science ®Google Scholar
• Prince AE , RocheMI. Genetic information, non-discrimination, and privacy protections in genetic counseling practice. J. Genet. Couns.23(6), 891–902 (2014).
   PubMed Web of Science ®Google Scholar
• Genetic Non-Discrimination Act Canadian Minister of Justice (2018).
   Google Scholar
• Yau A , HaqueM. Pharmacogenomics: knowledge, attitude and practice among future doctors and pharmacists – a pilot study. J. Appl. Pharm. Sci.6(2), 141–145 (2016).
   Google Scholar
• Lesko LJ , JohnsonJA. Academia at the crossroads: education and training in pharmacogenomics. Per. Med.9(5), 497–506 (2012).
   PubMed Web of Science ®Google Scholar
• Génome Québec, Inc . Introduction à la génomique, QC, Canada (2018). www.genomequebec-education-formations.com/formations.
   Google Scholar
• Mukerjee G , HustonA , KabakchievB , Piquette-MillerM , Van SchaikR , DorfmanR. User considerations in assessing pharmacogenomic tests and their clinical support tools. NPJ Genom. Med.3(26), (2018).
   PubMedGoogle Scholar
• Devine EB , LeeCJ , OverbyCLet al. Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: a mixed methods approach. Int. J. Med. Inform.83(7), 473–483 (2014).
   PubMed Web of Science ®Google Scholar
• Blagec K , KoopmannR , Crommentuijn-VanRhenen Met al. Implementing pharmacogenomics decision support across seven European countries: the ubiquitous pharmacogenomics (U-PGx) project. J. Am. Med. Inform. Assoc.25(7), 893–898 (2018).
   PubMed Web of Science ®Google Scholar